Keytruda-Lenvima Combo Better Than Sutent in Treating Kidney Cancer

Keytruda-Lenvima Combo Better Than Sutent in Treating Kidney Cancer

287573

Keytruda-Lenvima Combo Better Than Sutent in Treating Kidney Cancer

A combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) worked better than standard Sutent (sunitinib) at delaying disease progression and prolonging survival in adults with untreated advanced renal cell carcinoma (RCC) — the most common type of kidney cancer in adults — according to data from a Phase 3 clinical trial. In addition, Lenvima also outperformed Sutent in this patient population when combined with Afinitor (everolimus) — an approved second-line therapy for advanced RCC — but…

You must be logged in to read/download the full post.